Ability Biologics

Co-founder and CEO of Distributed Bio, Giles is an expert at building high performing capital efficient teams. He organically built Distributed Bio from 2 employees in 2010 to 30 in 2020, by structuring over 50 partnerships and licensing deals. He led the acquisition of Distributed Bio by Charles River Laboratories for over $100M up front with milestones and royalties. Prior to Distributed Bio Giles spent 15 years at Pfizer, where he held the position of Head of Informatics for the Biotherapeutics and Bioinnovation division. Giles holds a MSc in Computational Biology from the University of Manchester.

Jean-Philippe oversees the design strategies for the discovery and engineering programs as well as establishing the IP portfolio. Previously, JP was the Director of Bioinformatics at Charles River laboratories in South San Francisco, heading the scientific steering committee and R&D efforts at the site. Before that, he established the first US department of the international Bioinformatics, statistics and ML consulting firm BISC Global. He holds a PhD in computational immunology from the Luxembourg Institute of Health as well as a MSc in Biochemistry from the Technical University of Kaiserslautern. JP has accumulated over a decade of experience in immunoinformatics with a focus on antibody discovery and engineering.

Patrick is an executive with broad expertise in R&D and corporate development. He supports operations as well as strategic initiatives. Patrick was the Chief Corporate Development Officer at CellCarta where he led M&A activities completing 6 global acquisitions (for more than US$ 250M), diversifying services and growing the company across 10 sites and 3 continents. Prior to that, Patrick worked with Pappas Ventures, a venture capital firm investing in North American life sciences. He also held positions as Vice-President of R&D at BioAxone and as Director of Pharmacology at Neurochem where he worked on the development of drugs for systemic amyloidosis, Alzheimer’s disease and spinal cord injury. He also held a position of Assistant Professor in Neurology at the UCSF where he was part of the Nobel Team of Stanley Prusiner (1997). Patrick holds a Ph.D. in Molecular Biology from Montreal University and completed postdoctoral studies at the Max Planck Institute in Goettingen (Germany).

Patti is an experienced leader in drug discovery and development with strong track record for delivering biologic and small molecule candidates into the clinic in immune oncology and immunology. With a focus on understanding mechanism of action and clinical translation, Patti has held leadership positions in two early stage biotechs: Revitope Oncology, a company with a novel T cell engager platform where she led Biology and Northern Biologics where she established the translational sciences and bioanalytical teams while leading the company’s first clinical program. Patti began her career at Boehringer Ingelheim Pharmaceutical where she laid down a strong foundation in R&D, with experience from target identification through Phase I. She obtained her Ph.D. in Immunology from Yale University and conducted her postdoctoral studies at UCSF in the laboratory of Dr. Steven D. Rosen.

Elizabeth (Betsy) is a physician scientist who obtained her medical degree and PhD (Immunology) from the University of Toronto. Elizabeth completed a residency in internal medicine and a fellowship in Clinical Genetics at the Beth Israel Hospital and Children’s Hospital, respectively, in Boston, as well as a post-doctoral fellowship at the Dana-Farber Cancer Institute. In 2000, Elizabeth begin a 22 year journey in drug development, working in all phases from pre-clinical drug discovery through late stage clinical trial management.

Over the years, Elizabeth has held rising positions of leadership at both large pharmaceutical companies (Merck; Roche) and small biotechnology companies (Agennix; Celldex; and Elstar Therapeutics) and consulted for several more. Although she has worked across many different therapeutic areas (Cardiology, Autoimmunity, Neurology, Genetics), she has focused in the past decade on the development of large molecules and cells as immuno-oncology treatments (in particular, on T-cell engagers) and on gene therapies for rare disorders, working primarily as a Translational Medicine Expert.

Most recently, Matt was Sr. Director and Global Head of Data Analytics at Charles River Labs, where he introduced virtual control groups to in-vivo tests, replace control animals in preclinical studies using data science. Before that he led a global team of data scientists at Elsevier using AI, NLP, GAN and Bayesian statistics to address diverse problems in global drug development. Matt’s pharma experience includes Sr. Director of Computation at Locus Pharma, an AI-based pharma where the computational technology brought two programs to clinical trials as well as at AstraZeneca in safety sciences. He holds a PhD in chemistry from the University of Alabama.